Physician profile
Jerrylene David
NPI 1548043904
$2,129.65
in general payments reported to CMS, 2019-2025
15 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $367 · 2024: $1,377 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $890.62 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $365.33 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $194.00 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $113.89 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $111.19 | 2024 | |
| Pfizer INC. | $99.36 | 2024-2025 | |
| Lundbeck LLC | $74.71 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $71.75 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $61.00 | 2024-2025 | Veozah |
| Amgen INC. | $44.66 | 2024 | Repatha, Evenity, Prolia |
| Boston Scientific Corporation | $23.49 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.80 | 2023 | Rexulti |
| Philips North America LLC | $20.98 | 2024 | (Ck6) Holter |
| Watermark Medical, INC. | $19.01 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.86 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrylene David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.